ATE240942T1 - Neue substituierte aryl-verbindungen als acetylcholine receptors modulatoren - Google Patents
Neue substituierte aryl-verbindungen als acetylcholine receptors modulatorenInfo
- Publication number
- ATE240942T1 ATE240942T1 AT96940819T AT96940819T ATE240942T1 AT E240942 T1 ATE240942 T1 AT E240942T1 AT 96940819 T AT96940819 T AT 96940819T AT 96940819 T AT96940819 T AT 96940819T AT E240942 T1 ATE240942 T1 AT E240942T1
- Authority
- AT
- Austria
- Prior art keywords
- disorders
- compounds
- disease
- acetylcholine receptors
- dysfunction
- Prior art date
Links
- 108010009685 Cholinergic Receptors Proteins 0.000 title abstract 5
- 102000034337 acetylcholine receptors Human genes 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 7
- 208000035475 disorder Diseases 0.000 abstract 5
- 206010012289 Dementia Diseases 0.000 abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 238000006467 substitution reaction Methods 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 208000027534 Emotional disease Diseases 0.000 abstract 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 206010033799 Paralysis Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 150000001408 amides Chemical group 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000002567 autonomic effect Effects 0.000 abstract 1
- 230000004706 cardiovascular dysfunction Effects 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 229940124301 concurrent medication Drugs 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000008482 dysregulation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002148 esters Chemical group 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 230000027119 gastric acid secretion Effects 0.000 abstract 1
- 230000007661 gastrointestinal function Effects 0.000 abstract 1
- 230000005176 gastrointestinal motility Effects 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 150000002576 ketones Chemical group 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 230000006984 memory degeneration Effects 0.000 abstract 1
- 208000023060 memory loss Diseases 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- 230000007659 motor function Effects 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- 208000021090 palsy Diseases 0.000 abstract 1
- 239000004031 partial agonist Substances 0.000 abstract 1
- 208000028591 pheochromocytoma Diseases 0.000 abstract 1
- 230000000750 progressive effect Effects 0.000 abstract 1
- 230000020341 sensory perception of pain Effects 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 230000005062 synaptic transmission Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 150000003568 thioethers Chemical group 0.000 abstract 1
- 231100000397 ulcer Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55982195A | 1995-11-17 | 1995-11-17 | |
| PCT/US1996/018569 WO1997019059A1 (en) | 1995-11-17 | 1996-11-14 | Novel substituted aryl compounds useful as modulators of acetylcholine receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE240942T1 true ATE240942T1 (de) | 2003-06-15 |
Family
ID=24235168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96940819T ATE240942T1 (de) | 1995-11-17 | 1996-11-14 | Neue substituierte aryl-verbindungen als acetylcholine receptors modulatoren |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0874818B1 (de) |
| JP (1) | JP3969741B2 (de) |
| AT (1) | ATE240942T1 (de) |
| AU (1) | AU717012B2 (de) |
| CA (1) | CA2237752C (de) |
| DE (1) | DE69628333T2 (de) |
| ES (1) | ES2197255T3 (de) |
| WO (1) | WO1997019059A1 (de) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6362009B1 (en) | 1997-11-21 | 2002-03-26 | Merck & Co., Inc. | Solid phase synthesis of heterocycles |
| EP1068186A2 (de) | 1998-04-02 | 2001-01-17 | Targacept, Inc. | 3-pyridylalkoxyamine oder aryloxyalkylamine derivate als cholinergische agonisten |
| US6218383B1 (en) | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
| US6262124B1 (en) * | 1998-10-22 | 2001-07-17 | Gary Maurice Dull | Pharmaceutical compositions and methods for use |
| US20010031771A1 (en) | 1999-05-24 | 2001-10-18 | Gary Maurice Dull | Pharmaceutical compositions and methods for use |
| YU26700A (sh) * | 1999-05-24 | 2002-06-19 | Pfizer Products Inc. | Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin |
| US6784200B2 (en) | 2000-10-13 | 2004-08-31 | Bristol-Myers Squibb Pharma Company | Bicyclic and tricyclic amines as modulators of chemokine receptor activity |
| JP2003512355A (ja) | 1999-10-15 | 2003-04-02 | デュポン ファーマシューティカルズ カンパニー | ケモカイン受容体活性のモジュレータとしての二環式および三環式アミン |
| WO2003062224A1 (en) | 2002-01-17 | 2003-07-31 | Eli Lilly And Company | Aza-cyclic compounds as modulators of acetylcholine receptors |
| WO2003062235A1 (en) * | 2002-01-17 | 2003-07-31 | Eli Lilly And Company | Modulators of acetylcholine receptors |
| ZA200507486B (en) | 2003-03-07 | 2007-03-28 | Astellas Pharma Inc | Nitrogenous heterocyclic derivative having 2,6-disubstituted styryl |
| US20070191815A1 (en) | 2004-09-13 | 2007-08-16 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
| AU2005238296A1 (en) | 2004-04-30 | 2005-11-10 | Warner-Lambert Company Llc | Substituted morpholine compounds for the treatment of central nervous system disorders |
| ES2521494T3 (es) | 2007-04-02 | 2014-11-12 | Parkinson's Institute | Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos |
| US20110212928A1 (en) | 2010-02-09 | 2011-09-01 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| EP2968220B1 (de) | 2013-03-15 | 2021-05-05 | Agenebio, Inc. | Verfahren und zusammensetzungen zur verbesserung von kognitiven funktionen |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| WO2016123406A1 (en) | 2015-01-28 | 2016-08-04 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
| NZ738682A (en) | 2015-05-22 | 2022-01-28 | Agenebio Inc | Extended release pharmaceutical compositions of levetiracetam |
| WO2018129304A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| CN108383775A (zh) * | 2018-03-07 | 2018-08-10 | 泰州医药城国科化物生物医药科技有限公司 | 二芳基乙烯基环胺衍生物及其制备方法 |
| CA3101966A1 (en) | 2018-05-29 | 2019-12-05 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| AU2019358074A1 (en) * | 2018-10-10 | 2021-05-06 | Albert Einstein College Of Medicine | Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators |
| US12397141B2 (en) | 2018-11-16 | 2025-08-26 | Morningside Venture Investments Limited | Thermally regulated transdermal drug delivery system |
| CN114805237B (zh) * | 2021-01-22 | 2026-04-21 | 武汉人福创新药物研发中心有限公司 | 杂环类化合物的制备方法及其中间体 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4721783A (en) * | 1986-01-09 | 1988-01-26 | United Pharmaceuticals, Inc. | Anti-spasmodic agents having a heterocyclic ring |
| WO1994007489A1 (en) * | 1992-10-02 | 1994-04-14 | The Salk Institute For Biological Studies | Non-competitive inhibitors of neuronal nicotinic acetylcholine receptors |
| US5472958A (en) * | 1994-08-29 | 1995-12-05 | Abbott Laboratories | 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function |
| US5567710A (en) * | 1994-10-13 | 1996-10-22 | Sibia Neurosciences, Inc. | Polycyclic fused ring modulators of acetylcholine receptors |
-
1996
- 1996-11-14 ES ES96940819T patent/ES2197255T3/es not_active Expired - Lifetime
- 1996-11-14 AT AT96940819T patent/ATE240942T1/de not_active IP Right Cessation
- 1996-11-14 DE DE69628333T patent/DE69628333T2/de not_active Expired - Lifetime
- 1996-11-14 WO PCT/US1996/018569 patent/WO1997019059A1/en not_active Ceased
- 1996-11-14 JP JP51984997A patent/JP3969741B2/ja not_active Expired - Fee Related
- 1996-11-14 EP EP96940819A patent/EP0874818B1/de not_active Expired - Lifetime
- 1996-11-14 AU AU10782/97A patent/AU717012B2/en not_active Ceased
- 1996-11-14 CA CA002237752A patent/CA2237752C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2000501080A (ja) | 2000-02-02 |
| WO1997019059A1 (en) | 1997-05-29 |
| EP0874818A1 (de) | 1998-11-04 |
| CA2237752C (en) | 2006-05-16 |
| CA2237752A1 (en) | 1997-05-29 |
| EP0874818B1 (de) | 2003-05-21 |
| AU717012B2 (en) | 2000-03-16 |
| JP3969741B2 (ja) | 2007-09-05 |
| DE69628333D1 (de) | 2003-06-26 |
| DE69628333T2 (de) | 2004-04-08 |
| ES2197255T3 (es) | 2004-01-01 |
| AU1078297A (en) | 1997-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69628333D1 (de) | Neue substituierte aryl-verbindungen als acetylcholine receptors modulatoren | |
| ATE271040T1 (de) | Substituierte pyridinderivate, deren herstellung und deren verwendung als modulatoren von acetylcholin-rezeptoren | |
| ATE248160T1 (de) | Pyridin acetylcholin-rezeptor-modulatoren | |
| TR199700644T1 (xx) | Serotonin-ili�kili sistemler �zerinde etkiye sahip bile�ikler. | |
| WO2000070049A3 (en) | Extracellular signaling molecules | |
| MY138267A (en) | Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use | |
| IL124728A0 (en) | Diagnosis and treatment of aur-1 and/or aur-2 related disorders | |
| PT1003863E (pt) | Receptor-11 de citoquinas de mamifero | |
| HU9400728D0 (en) | Fused tricyclic nitrogen containing heterocycles as substance p receptor antagonists | |
| DE69528823D1 (en) | Morpholinwirkstoffvorläufer als tachykininreceptorantagonisten | |
| BG106508A (en) | Alkylene diamine-substituted heterocycles | |
| ATE321855T1 (de) | Tumor-nekrose-faktor rezeptor 5 | |
| WO2001055202A8 (en) | Nucleic acids, proteins, and antibodies | |
| WO2001054472A3 (en) | Nucleic acids, proteins, and antibodies | |
| Oki et al. | Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice | |
| Fernández et al. | Spirolactams as conformationally restricted pseudopeptides: synthesis and conformational analysis | |
| ATE432938T1 (de) | Substituierte 1-oxa-3,8-diazaspiroä4.5ü-decan-2- on-verbindungen und deren verwendung zur herstellung von arzneimitteln | |
| DE3752062D1 (de) | Verwendung von heterozyklischen Derivaten zur Herstellung von Arzneimitteln | |
| ATE245632T1 (de) | Benzodiazepin derivate verwendbar als cck- rezeptoren antagonisten | |
| Manetti et al. | Design, synthesis, and preliminary pharmacological evaluation of 1, 4-diazabicyclo [4.3. 0] nonan-9-ones as a new class of highly potent nootropic agents | |
| Malany et al. | Orientation of α-neurotoxin at the subunit interfaces of the nicotinic acetylcholine receptor | |
| Bittermann et al. | Evaluation of lactam-bridged neurotensin analogues adjusting ψ (Pro10) close to the experimentally derived bioactive conformation of NT (8− 13) | |
| GR3034602T3 (en) | Novel n-(2,4-dioxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepin-3y l)-3-amides | |
| McDonald et al. | 2, 7-Dioxo-2, 3, 4, 5, 6, 7-hexahydro-1 H-benzo [h][1, 4] diazonine as a new template for the design of CCK2 receptor antagonists | |
| Proniewicz et al. | Role of Phe‐D5 isotopically labeled analogues of bradykinin on elucidation of its adsorption mode on Ag, Au, and Cu electrodes. Surface‐enhanced Raman spectroscopy studies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |